CSL Of Australia Considers Doubling Seasonal Flu Vaccine Production
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL is considering production of twice the seasonal influenza vaccine it had planned for the next fiscal year. The company decided on the move after U.S. pre-season orders reserved nearly all of the production originally planned. In demand is CSL's Afluria, expected to be worth $80 million in sales in the year that begins July 1. The U.S. military is expected to be a major buyer of the batch of 9 million doses exported by CSL. A market analyst said the U.S. order might be driven by the increased flu awareness brought on by the H1N1 pandemic. (Click here for more
You may also be interested in...
First Out Of The Gate, CSL Begins Adult Trials Of H1N1 Flu Vaccine
PERTH, Australia - Melbourne-headquartered CSL Limited will begin clinical trials of its H1N1 influenza vaccine in healthy adults ages 18 to 64 July 22, and pediatric trials will commence Aug. 1, CSL said
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.